CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment - Concepedia

Concepedia

Publication | Closed Access

CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment

341

Citations

26

References

2014

Year

Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gramlich, Maryann Gallagher, Priti Lal, Michael D. Feldman, Paul J. Zhang, Christopher Colameco,

Clinical Cancer Research

Abstract

Single-agent palbociclib is well tolerated and active in patients with endocrine-resistant, HR(+), Rb-positive breast cancer. Cytopenias were uncomplicated and easily managed with dose reduction.

References

	Year	Citations

Page 1